9920 Jefferson Boulevard
89 articles with NantKwest
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
NantKwest, a leading clinical-stage, natural killer cell based therapeutics company, announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong, will be giving a keynote address at the Innate Killer Summit in San Diego on Wednesday, March 20, 2019.
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
NantKwest today announced that the company will be hosting an Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco, California.
NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials
NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2nd in New York City During the conference, company management will be presenting a corporate overview, as well as conducting one-on-one meetings to provide a corporate update, as well as review R&D and clinical activities.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
NantKwest, Inc. announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO).
NantKwest announced that Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest, will be presenting and conducting one-on-one meetings at the upcoming Jefferies Global Healthcare Conference
NantKwest announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the month of March and April 2018.
Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
The study is being led by Dr. Michael Burger, principal investigator, together with co-principal investigators Professor Joachim Steinbach, Head of the Institute for Neuro-oncology at the Goethe University Hospital, and Professor Christian Senft, Department of Neurosurgery at the Goethe University Hospital in Frankfurt/Main, Germany.
NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine
NantKwest announced today that the company will be hosting an Investor/Analyst Day on Tuesday, January 9th in San Francisco, California.
This oral presentation will present preclinical data on the company’s CD19.taNK program.
NantKwest Announces Successful First In Human Administration Of CD16 High Affinity Natural Killer (haNK) Cells
NantKwest Builds Financial And Commercial Expertise With The Appointment Of Fred Driscoll To Its Board Of Directors
NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies
NantKwest Announces Publication Of Preclinical Data Of Hank Cell Therapy In Combination With Checkpoint Inhibitor Avelumab Providing Strong Rationale For Advancement To Human Clinical Trials
NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages Of Disease